Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.
You may also be interested in...
What Does Pfizer’s Read Have To Say About It? A Lot, Actually
Pfizer CEO Ian Read voiced his opinions on some of industry’s hottest topics – everything from the pricing of Sovaldi to M&A to the latest innovations, like gene therapy – during a far-ranging discussion at the BIO CEO & Investor conference Feb. 10.
Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business
Beginning in January 2014, Pfizer is realigning its commercial operations into three organizations, in effect taking the next step on its multi-year deliberation over whether to split up its behemoth business.
Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business
Beginning in January 2014, Pfizer is realigning its commercial operations into three organizations, in effect taking the next step on its multi-year deliberation over whether to split up its behemoth business.